A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Sarcoma|Carcinoma|Digestive Cancer|Breast Cancer|Lung Cancer|Brain Cancer|Melanoma|Gynecologic Cancer|Head and Neck Cancer|Kidney Cancer
Interventions: DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)
Sponsor: Shanghai Yunying Medical Technology
Collaborators: Linyi Central Hospital